Personal information

Denmark

Activities

Employment (1)

Herlev Hospital Onkologisk Afdeling: Herlev, DK

2018-04-01 to present | Postdoctoral fellow (National Center for Cancer Immune Therapy (CCIT-DK))
Employment
Source: Self-asserted source
Gitte Holmen Olofsson

Education and qualifications (2)

University of Copenhagen: Copenhagen, DK

2018-04-13 | Ph.D. degree in Immunology and infectious Diseases
Education
Source: Self-asserted source
Gitte Holmen Olofsson

University of Copenhagen: Copenhagen, DK

2010 to 2012 | MSc. Molecular Biomedicin
Qualification
Source: Self-asserted source
Gitte Holmen Olofsson

Works (13)

High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI AIM) - a randomized controlled trial.

BMC cancer
2022-03-05 | Journal article
Source: Self-asserted source
Gitte Holmen Olofsson

Vg9Vd2 T Cells Concurrently Kill Cancer Cells and Cross- Present Tumor Antigens

Frontiers in Immunology
2021 | Journal article
Source: Self-asserted source
Gitte Holmen Olofsson

The capacity of CD4+ Vγ9Vδ2 T cells to kill cancer cells correlates with co-expression of CD56.

Cytotherapy
2021-03 | Journal article
Part of ISSN: 1477-2566
Source: Self-asserted source
Gitte Holmen Olofsson

Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?

Cancers
2021-01 | Journal article
Part of ISBN: 4538682675
Part of ISSN: 2072-6694
Source: Self-asserted source
Gitte Holmen Olofsson
grade
Preferred source (of 2)‎

Expansion With IL-15 Increases Cytotoxicity of V$γ$9V$δ$2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet.

Frontiers in immunology
2020 | Journal article
Part of ISSN: 1664-3224
Source: Self-asserted source
Gitte Holmen Olofsson

Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo.

International journal of molecular sciences
2020-05 | Journal article
Part of ISSN: 1422-0067
Source: Self-asserted source
Gitte Holmen Olofsson

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.

Cancer immunology research
2019-07 | Journal article
Part of ISSN: 2326-6074
Source: Self-asserted source
Gitte Holmen Olofsson

Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model.

Oncoimmunology
2018 | Journal article
Part of ISSN: 2162-4011
Source: Self-asserted source
Gitte Holmen Olofsson

Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.

Cell metabolism
2016-03 | Journal article
Part of ISSN: 1932-7420
Source: Self-asserted source
Gitte Holmen Olofsson

Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer

OncoImmunology
2015 | Journal article
Part of ISBN:

2162-4011 (Print)$\backslash$r2162-4011

Part of ISSN: 2162-402X
Source: Self-asserted source
Gitte Holmen Olofsson

Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells.

Leukemia
2013-11 | Journal article
Part of ISSN: 1476-5551
Source: Self-asserted source
Gitte Holmen Olofsson

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells.

Oncoimmunology
2013-04 | Journal article
Part of ISSN: 2162-4011
Source: Self-asserted source
Gitte Holmen Olofsson

HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.

Cancer research
2013-03 | Journal article
Part of ISSN: 1538-7445
Source: Self-asserted source
Gitte Holmen Olofsson